文献速递临床试验与 GCP基础与转化研究

中西医结合治疗较低危骨髓增生异常综合征贫血:随机安慰剂对照试验方案

Integrated traditional Chinese and conventional medicine in the treatment of anemia due to lower-risk myelodysplastic syndrome: study protocol for a randomized placebo-controlled trial.
PubMed 文献 · Trials · 2021-10-18

本研究为前瞻性、多中心、双盲、随机安慰剂对照试验,计划纳入60例较低危骨髓增生异常综合征(MDS)贫血患者,比较常规药物联合益宫散(YGS)与常规药物联合安慰剂的疗效。主要结局为血红蛋白水平,次要结局包括中医症状评分、铁代谢、hepcidin水平及炎症因子。

要点

  • 试验评估YGS联合常规药物治疗较低危MDS贫血的有效性与可行性。
  • 主要结局为血红蛋白水平,次要结局涵盖铁代谢与炎症指标。
  • 口服用药每日两次,持续3个月,全程随访。

核心结论

  • 该试验旨在验证YGS治疗较低危MDS贫血的有效性和可行性,并评估其对炎症因子和铁代谢的影响。

研究设计与样本

  • 前瞻性、多中心、双盲、随机安慰剂对照临床试验,计划纳入60例较低危MDS贫血患者,每组30例。

主要发现

  • 原文未报告试验结果,仅描述研究方案。

关键数值与推荐

  • 主要结局为血红蛋白水平;次要结局包括中医症状评分、铁代谢、hepcidin水平及炎症因子。
  • 口服药物每日两次,持续3个月,全程随访3个月。

临床怎么用

  • 若试验证实有效,可为较低危MDS贫血的中西医结合治疗提供科学依据。

局限性

  • 样本量较小(共60例),可能影响结果的外推性。
  • 随访时间较短(3个月),长期疗效未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Erythropoiesis and iron homeostasis are closely related; anemia due to lower-risk myelodysplastic syndromes (MDS) remains difficult to treat. In the last decade, we have been committed to improving the regulation of iron metabolism using traditional Chinese medicine (TCM). Previous studies have found that the TCM Yi Gong San (YGS) can reduce the expression of transferrin by inhibiting hepcidin overexpression caused by inflammation, promote the outward transfer of intracellular iron, and improve the symptoms of anemia. Here, our study aimed to compare the efficacy of a conventional drug with YGS with that of conventional medicine with placebo to provide a scientific basis for making clinical decisions. METHODS: A prospective, multicenter, double-blinded, randomized controlled clinical trial will be conducted to evaluate the therapeutic efficacy of conventional medicine combined with YGS with that of conventional medicine alone in the treatment of MDS. A total of 60 patients would be enrolled in this study, with each treatment group (conventional medicine + YGS and conventional medicine + placebo) comprising 30 patients. Oral medication would be administered twice daily for 3 months. All patients would be followed up throughout the 3-month period. The primary outcome was measured by assessing blood hemoglobin level. The secondary outcome was measured by assessing TCM symptom score, iron metabolism, hepcidin levels, and inflammatory factors. DISCUSSION: This trial would aim to demonstrate the effectiveness and feasibility of YGS in the treatment of lower-risk MDS anemia, as well as its impact on inflammatory factors and iron metabolism in patients with lower-risk MDS. TRIAL REGISTRATION: Chinese Clinical Trials Registry ( http://www.chictr.org.cn/ ) ChiCTR1900026774 . Registered on October 21, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zheng Q, Xu H, Song L, et al. Integrated traditional Chinese and conventional medicine in the treatment of anemia due to lower-risk myelodysplastic syndrome: study protocol for a randomized placebo-controlled trial. Trials. 2021. PMID: 34663434. doi:10.1186/s13063-021-05646-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。